Loading
Life sciences · Review
Molecular Biomedicine · November 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Review.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Super-enhancers (SEs) are operationally defined as clusters of cis-regulatory elements associated with high transcriptional activity and cell-identity genes. They display dense transcription factor and coactivator occupancy, strong H3K27 acetylation, and enhancer-promoter communication, but their annotation varies across platforms, algorithms, and thresholds. This review examines SE architecture, identification, and validation, distinguishing chromatin-based annotation from functional dependence demonstrated by locus-specific perturbations. Mechanisms of SE-associated transcription include pioneer factors, chromatin remodelers, three-dimensional genome organization, transcriptional condensates, non-coding RNAs, and extrachromosomal DNA. Physiological functions in development, immunity, and metabolic homeostasis are considered alongside context-dependent dysregulation in cancer, inflammatory and autoimmune diseases, neurological disorders, and metabolic diseases. Breast cancer provides a model for examining subtype-specific regulation and transcriptional plasticity. Particular attention is given to enhancer remodeling during endocrine therapy, cyclin-dependent kinase 4/6 (CDK4/6) inhibition, human epidermal growth factor receptor 2 (HER2)-targeted treatment, and chemotherapy, which may support bypass signaling, stemness, and persistent resistance. Causal regulatory changes must nevertheless be distinguished from correlates of treatment selection. Therapeutic approaches targeting bromodomain and extraterminal domain (BET) proteins, CDK7/9, chromatin regulators, enhancer RNAs, and regulatory loci are critically evaluated. Definitional uncertainty, model dependence, limited reproducibility, systemic toxicity, and insufficient clinical validation remain major barriers. Priorities include standardized annotation, temporally resolved perturbation, single-cell and spatial profiling, artificial intelligence-assisted integration, patient-derived models, and biomarker-guided therapeutic development. Together, these perspectives position SEs as a context-dependent framework linking regulatory architecture to disease progression and treatment resistance, while emphasizing the evidence required to establish therapeutic vulnerabilities.